Premium
An evaluation of recombinant leukocyte a interferon with aspirin in patients with metastatic renal cell cancer
Author(s) -
Creagan Edward T.,
Buckner Jan C.,
Hahn Richard G.,
Richardson Ronald R.,
Schaid Daniel J.,
Kovach John S.
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880501)61:9<1787::aid-cncr2820610911>3.0.co;2-q
Subject(s) - medicine , aspirin , alpha interferon , clinical trial , cancer , oncology , renal cell carcinoma , alpha (finance) , interferon alfa , interferon , immunology , surgery , construct validity , patient satisfaction
The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leakocyte A interferon (IFN‐α2A), 20 × 10 6 U/m 2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN‐α2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well‐recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN‐α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN‐α2A in patients with advanced RCC.